share_log

Maxim Group Initiates Coverage On Belite Bio With Buy Rating, Announces Price Target of $60

Benzinga ·  Dec 14, 2023 09:11

Maxim Group analyst Jason McCarthy initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $60.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment